SPR-based fragment screening with neurotensin receptor 1 generates novel small molecule ligands

PloS One
Sylwia HuberMichael Hennig

Abstract

The neurotensin receptor 1 represents an important drug target involved in various diseases of the central nervous system. So far, the full exploitation of potential therapeutic activities has been compromised by the lack of compounds with favorable physicochemical and pharmacokinetic properties which efficiently penetrate the blood-brain barrier. Recent progress in the generation of stabilized variants of solubilized neurotensin receptor 1 and its subsequent purification and successful structure determination presents a solid starting point to apply the approach of fragment-based screening to extend the chemical space of known neurotensin receptor 1 ligands. In this report, surface plasmon resonance was used as primary method to screen 6369 compounds. Thereby 44 hits were identified and confirmed in competition as well as dose-response experiments. Furthermore, 4 out of 8 selected hits were validated using nuclear magnetic resonance spectroscopy as orthogonal biophysical method. Computational analysis of the compound structures, taking the known crystal structure of the endogenous peptide agonist into consideration, gave insight into the potential fragment-binding location and interactions and inspires chemistry efforts for fu...Continue Reading

References

May 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·P KitabgiP Freychet
Jan 1, 1995·Fundamental & Clinical Pharmacology·D GullyJ P Maffrand
Aug 1, 1997·Progress in Neurobiology·T Jolas, G K Aghajanian
Jul 18, 2002·Nature Reviews. Drug Discovery·Tom L BlundellChris Abell
May 20, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kimberly A PetrieAriel Y Deutch
Jun 1, 2004·The American Journal of Psychiatry·Herbert Y MeltzerUNKNOWN Meta-Trial Study Group
Mar 31, 2005·Analytical Biochemistry·Iva NavratilovaDavid G Myszka
Feb 21, 2006·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Hassan Pajouhesh, George R Lenz
Jun 10, 2006·Analytical Biochemistry·Iva NavratilovaDavid G Myszka
Nov 15, 2006·Current Pharmaceutical Design·Walter Huber, Francis Mueller
May 1, 2009·Journal of Biomolecular Screening·Samantha PerspicaceWalter Huber
May 12, 2009·Drug Discovery Today·Gianni Chessari, Andrew J Woodhead
Sep 3, 2010·Current Topics in Medicinal Chemistry·Ramón Campos-Olivas
Oct 26, 2010·Analytical Biochemistry·Rebecca L RichDavid G Myszka
Mar 5, 2011·Methods in Enzymology·Miles CongreveFiona H Marshall
Aug 13, 2011·Topics in Current Chemistry·Michael HennigWalter Huber
May 19, 2012·Nature Reviews. Drug Discovery·Guy Griebel, Florian Holsboer
Jun 16, 2012·Biochemistry·Duncan E ScottChris Abell
Jul 13, 2012·Trends in Biochemical Sciences·Christopher G Tate
Oct 12, 2012·Nature·Jim F WhiteReinhard Grisshammer
Oct 13, 2012·Nature Reviews. Drug Discovery·Gideon BollagPeter Hirth
Nov 21, 2012·Journal of Molecular Biology·Daniel J Scott, Andreas Plückthun
May 21, 2013·Journal of Biomolecular NMR·Mary J HarnerStephen W Fesik
Jan 24, 2014·Proceedings of the National Academy of Sciences of the United States of America·Pascal EgloffAndreas Plückthun
Jan 24, 2014·ACS Medicinal Chemistry Letters·Tonia AristotelousIva Navratilova
Feb 18, 2014·The Journal of Clinical Investigation·Michel DemeulePhilippe Sarret
Jan 1, 2013·The Enzymes·Till Maurer, Weiru Wang
Jul 30, 2014·Biochimica Et Biophysica Acta·Daniel J ScottAndreas Plückthun
Sep 2, 2014·Progress in Biophysics and Molecular Biology·David M Dias, Alessio Ciulli
Oct 11, 2014·Progress in Biophysics and Molecular Biology·Claire A ShepherdIva Navratilova

❮ Previous
Next ❯

Citations

Nov 28, 2018·Journal of Biomolecular Structure & Dynamics·M Rejwan AliMihaly Mezei
Dec 14, 2019·Expert Opinion on Drug Discovery·Asko Uri, Olivier Etebe Nonga
Apr 30, 2020·SLAS Discovery·Joe Coyle, Reto Walser
May 21, 2020·Future Medicinal Chemistry·Xingui LiuDaohong Zhou
Mar 13, 2021·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Genevieve E CampbellDiane M Duffy
Apr 4, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Yann WaltenspühlAndreas Plückthun

❮ Previous
Next ❯

Methods Mentioned

BETA
NMR
X-ray
Surface Plasmon Resonance
Nuclear Magnetic Resonance
chips
biosensor

Software Mentioned

Topspin
XLfit
GraphPadPrism
Gold
BiaEvaluation

Related Concepts

Related Feeds

Blood-Brain Barrier Transport in Neurodegeneration

The blood brain barrier is important for regulating the movement of biomolecules in and out of the brain. For example, membrane transporters in the blood brain barrier can be essential for regulating drug movement and dysregulation of these processes may play a role in neurodegeneration. This feed follows the latest research on this topic.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.